What does unrealized gains on investments mean?

This represents the cumulative increase in the fair market value of investment securities held by the company that have not yet been sold. It reflects the performance of the company's treasury or investment portfolio in the current market environment. This metric is a key indicator of the unrealized wealth generated from capital allocation strategies.

Esperion Therapeutics ESPR Unrealized Gains on Investments

Unrealized Gains on Investments at other companies

Nurix Therapeutics, Inc.NRIX

$88K—

AmgenAMGN

——

BridgeBio PharmaBBIO

——

Nektar TherapeuticsNKTR

——

BioCryst PharmaceuticalsBCRX

——

Absci CorporationABSI

——

Other financials

Income statement

See full

Revenue$80.1M+23.2%

Operating income-$6.6M+70.2%

Net income-$25.2M+37.7%

EPS (diluted)-$0.10+52.4%

Balance sheet

See full

Cash & equivalents$156.2M+36.2%

Total debt$155.2M+6.1%

Total equity-$307.9M+27.8%

Total assets$462.5M+42.7%

Cash flow

See full

Operating cash flow-$27.7M-22.5%

CapEx$189.0K—

Free cash flow-$27.9M-23.3%

Valuation

See full

Market cap$811.73M+283%

Enterprise value$810.81M+233%

P/S1.9×+1.1×

Profitability

See full

Operating margin18.1%+12.7pp

Net margin-34.8%+8.0pp

FCF margin-30.7%—

Returns & leverage

See full

Return on equity-260.8%—

Debt / equity0.8×—

Current ratio1.5×+0.4×

Where this comes from

Reported directly by Esperion Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.

The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Esperion Therapeutics's unrealized gains on investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Esperion Therapeutics's unrealized gains on investments?: Esperion Therapeutics (ESPR) reported unrealized gains on investments of $0 in Q1 2026.
What does unrealized gains on investments mean?: This represents the cumulative increase in the fair market value of investment securities held by the company that have not yet been sold. It reflects the performance of the company's treasury or investment portfolio in the current market environment. This metric is a key indicator of the unrealized wealth generated from capital allocation strategies.